Trial Profile

Phase 2 Proof of Concept Study of Nivolumab and Ipilimumab in Children and Young Adults With Relapsed or Refractory INI1-negative Cancers

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Cancer; Chordoma; CNS cancer; Rhabdoid tumour; Sarcoma; Solid tumours; Teratoma
Focus Proof of concept; Therapeutic Use

Most Recent Events

13 Sep 2024 Planned End Date changed from 1 Oct 2025 to 1 Dec 2025.
13 Sep 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Jun 2025.
06 Mar 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com